Donepezil Hydrochloride: Difference between revisions

From SEHK Wiki
Helen (talk | contribs)
Helen (talk | contribs)
Line 71: Line 71:
|Donepezil hydrochloride is readily absorbed from the gastrointestinal tract with a relative oral bioavailability of 100%. It is about 95% bound to plasma proteins, mainly albumin.
|Donepezil hydrochloride is readily absorbed from the gastrointestinal tract with a relative oral bioavailability of 100%. It is about 95% bound to plasma proteins, mainly albumin.
|-
|-
!style="text-align: left"| Neuropathic Pain
!style="text-align: left"| Onset of action
|By mouth:
|Peak plasma levels in 3-4 hours
*300 mg once daily on day 1, then
*300 mg twice daily on day 2, then
*300 mg 3 times daily on day 3.
 
Alternatively, 300 mg 3 times daily on day 1, then increased according to response in steps of 300mg (in 3 divided doses) every 2-3 days up to max. 3.6 g daily.


|-
|-
!style="text-align: left"| Migraine prophylaxis
!style="text-align: left"| Elimination half-life
|By mouth:
|70 hours, but around 100 hours in elderly
*initially 300 mg daily, increased according to response up to 2.4 g daily in divided doses.
|-
 
!Duration of action
|With daily dosing, steady-state concentration is reached within 3 weeks after initiation of therapy. Once at steady-state, plasma donepezil hydrochloride concentrations show little variability over the course of the day.
|}
|}

Revision as of 23:06, 29 September 2020

Pronunciation

Donepezil hydrochloride 10mg (ARICEPT 10mg)

Donepezil hydrochloride 5mg (ARICEPT 5mg)

Introduction

Donepezil hydrochloride, is a reversible inhibitor of acetylcholinesterase. It is used for the treatment of mild to moderate dementia in Alzheimer’s disease.


Generic Name 藥名 HA Code 藥物代碼 Classification藥物分類
Donepezil HCL Tablet 5mg DONE01 P1S1S3
Donepezil HCL Tablet 10mg DONE02 P1S1S3
Donepezil HCL Orodispersible Tablet 5mg DONE03 P1S1S3


Mechanism of Action

Acetylcholinesterase inhibiting drug


Dosage

By Oral: initially 5 mg once daily at bedtime, increased if necessary, after one month to max. 10 mg daily.

Clinical benefit should be assessed on a regular basis. Up to half the patients will show a slower rate of cognitive decline. Donepezil should be discontinued in those not responding.


Side Effects

Common side effects include

  • Nausea and vomiting
  • difficulty sleeping
  • aggression
  • Loss of appetite
  • Diarrhoea
  • Feeling tired
  • Muscle cramps

These effects usually last 1 – 3 weeks and then lessen

Serious side effects may include:

  • Abnormal heart rhythms
  • Difficulty emptying urine from the bladder
  • seizures

Donepezil, like other acetylcholinesterase inhibitors, can cause nightmares due to enhanced activation of the visual association cortex during REM sleep. Taking donepezil in the morning can reduce the frequency of nightmares.


Pharmacokinetics

Oral bioavailability Donepezil hydrochloride is readily absorbed from the gastrointestinal tract with a relative oral bioavailability of 100%. It is about 95% bound to plasma proteins, mainly albumin.
Onset of action Peak plasma levels in 3-4 hours
Elimination half-life 70 hours, but around 100 hours in elderly
Duration of action With daily dosing, steady-state concentration is reached within 3 weeks after initiation of therapy. Once at steady-state, plasma donepezil hydrochloride concentrations show little variability over the course of the day.